Criteria for Evaluation of Novel Markers of Cardiovascular RiskMark A. Hlatky, Peter W.F. Wilson, Sidney C. Smith et al.|Circulation|2009Cited by 1.1k
Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic CardiomyopathySara Saberi, Daniel Jacoby, Nuno Cardim et al.|Circulation|2020Cited by 234
Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic CardiomyopathyMartin S. Maron, Theodore P. Abraham, Timothy C. Wong et al.|Journal of the American College of Cardiology|2023Cited by 192
Society for Cardiovascular Magnetic Resonance (SCMR) expert consensus for CMR imaging endpoints in clinical research: part I - analytical validation and clinical qualificationValentina O. Püntmann, Jos J.M. Westenberg, Rocío Hinojar et al.|Journal of Cardiovascular Magnetic Resonance|2018Cited by 153
2022 ACC/AHA guideline for the diagnosis and management of aortic diseaseEric M. Isselbacher, Patrick T. O’Gara, Beau Hawkins et al.|Journal of Thoracic and Cardiovascular Surgery|2023Cited by 125